Edition:
India

Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

44.32EUR
16 Oct 2019
Change (% chg)

-- (--)
Prev Close
€44.32
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,743,891
52-wk High
€69.02
52-wk Low
€38.28

Latest Key Developments (Source: Significant Developments)

Fresenius Kabi - Announced Immediate Availability In United States Of Phenylephrine Hydrochloride Injection, Usp
Friday, 30 Aug 2019 

Aug 30 (Reuters) - Fresenius SE & Co KGaA ::FRESENIUS KABI - ANNOUNCED IMMEDIATE AVAILABILITY IN UNITED STATES OF PHENYLEPHRINE HYDROCHLORIDE INJECTION, USP.FRESENIUS KABI - PHENYLEPHRINE HYDROCHLORIDE INJECTION, USP IS GENERIC EQUIVALENT TO VAZCULEP, WHICH IS REGISTERED TRADEMARK OF AVADEL PHARMACEUTICALS.  Full Article

Fresenius CEO Says Open For More Hospital M&A Activities In Spain
Tuesday, 30 Jul 2019 

July 30 (Reuters) - Fresenius SE & Co KGaA in call::CEO SAYS I AM OPEN TO DOING MORE HOSPITAL M&A IN SPAIN IN PARTICULAR, SELECTIVELY IN GERMANY AND OPPORTUNISTICALLY IN LATIN AMERICA.CEO SAYS WE ARE MORE OPEN NOW TO RE-EMBRACE THE ORIGINAL PLAN TO POTENTIALLY LOOK AT A THIRD EUROPEAN COUNTRY MARKET IN 2020 AND BEYOND.  Full Article

U.S. FDA Says Fresenius Kabi USA Issues Voluntary Nationwide Recall Of Two Lots Of Fluorouracil Injection
Wednesday, 3 Jul 2019 

July 2 (Reuters) - U.S. Food and Drug Administration::U.S. FDA SAYS FRESENIUS KABI USA ISSUES VOLUNTARY NATIONWIDE RECALL OF TWO LOTS OF FLUOROURACIL INJECTION DUE TO THE POTENTIAL FOR GLASS PARTICULATE.  Full Article

Fresenius Kabi Initiates Voluntary U.S. Recall Of Volumat MC Agilia Infusion System And Vigilant Drug’Lib
Saturday, 29 Jun 2019 

June 28 (Reuters) - Fresenius Kabi USA::FRESENIUS KABI INITIATES VOLUNTARY U.S. RECALL OF VOLUMAT MC AGILIA™ INFUSION SYSTEM AND VIGILANT DRUG’LIB™ DUE TO SOFTWARE ANOMALIES, END OF INFUSION ALARM.FRESENIUS KABI USA - VOLUNTARY U.S. RECALL OF VOLUMAT MC AGILIA INFUSION SYSTEM & VIGILANT DRUG'LIB BEING CONDUCTED WITH KNOWLEDGE OF U.S. FDA.FRESENIUS KABI USA - TO DATE, FRESENIUS KABI HAS NOT RECEIVED ANY REPORTS OF ADVERSE EVENTS RELATED TO SOFTWARE ANOMALIES.FRESENIUS KABI USA - WILL UPGRADE SOFTWARE APPLICATIONS, ALARM AFFECTED BY VOLUNTARY U.S. RECALL OF VOLUMAT MC AGILIA INFUSION SYSTEM, VIGILANT DRUG'LIB.FRESENIUS KABI USA - WILL UPGRADE VOLUMAT MC AGILIA VOLUMETRIC INFUSION PUMPS' "KEEP VEIN OPEN (KVO), END OF INFUSION" ALARM TO A HIGH-PRIORITY ALARM.FRESENIUS KABI USA - THERE HAVE BEEN NO INJURIES OR DEATHS REPORTED IN U.S. RELATED TO "KEEP VEIN OPEN (KVO), END OF INFUSION" ALARM.FRESENIUS KABI USA - THERE HAS BEEN ONE DEATH REPORTED OUTSIDE OF U.S. RELATED TO "KEEP VEIN OPEN (KVO), END OF INFUSION" ALARM.  Full Article

Fresenius says rules out meaningful restructuring charges in 2019
Friday, 7 Dec 2018 

Dec 7 (Reuters) - Fresenius SE & Co KGaA ::CEO SAYS RULES OUT MEANINGFUL RESTRUCTURING CHARGES IN 2019.  Full Article

Fresenius SE & Co Expects Mid-Single Digit Organic Growth In The Medium-Term, After Strong Investment Year 2019
Friday, 7 Dec 2018 

Dec 6 (Reuters) - :DGAP-ADHOC: FRESENIUS SE & CO. KGAA: FRESENIUS EXPECTS MID-SINGLE DIGIT ORGANIC GROWTH IN THE MEDIUM-TERM, AFTER STRONG INVESTMENT YEAR 2019.GIVEN ITS CURRENT EXPECTATIONS FOR FY 2018 AND FY 2019, FRESENIUS NOW BELIEVES ITS AMBITIOUS GROUP TARGETS FOR 2020 WILL NOT BE MET.FROM 2020 ONWARDS, FRESENIUS NOW EXPECTS SUSTAINABLE ORGANIC GROUP SALES GROWTH IN MID-SINGLE DIGITS.FRESENIUS EXPECTS MID-SINGLE DIGIT ORGANIC SALES GROWTH FOR FY 2019.FY 2019 GROUP NET INCOME IS EXPECTED TO BE BROADLY STABLE OVER FY 2018.FROM 2020 ONWARDS GROUP NET INCOME IS EXPECTED TO GROW ORGANICALLY SLIGHTLY FASTER THAN SALES.UPON FRESENIUS KABI'S BIOSIMILARS BUSINESS BREAKING EVEN, FRESENIUS EXPECTS AN ACCELERATION OF GROUP EARNINGS GROWTH.  Full Article

Fresenius Kabi USA Issues Voluntary Nationwide Recall of Sodium Chloride Injection, USP, 0.9%
Wednesday, 21 Nov 2018 

Nov 20 (Reuters) - Fresenius Kabi USA::FRESENIUS KABI ISSUES VOLUNTARY NATIONWIDE RECALL OF SODIUM CHLORIDE INJECTION, USP, 0.9% DUE TO PRODUCT LABELING INCORRECTLY STATING STOPPERS DO NOT CONTAIN LATEX.FRESENIUS KABI USA SAYS VOLUNTARILY RECALLING 163 LOTS OF SODIUM CHLORIDE INJECTION, USP, 0.9% 10 ML FILL IN A 10 ML VIAL & 20 ML FILL IN A 20 ML VIAL.FRESENIUS KABI USA SAYS TO DATE, CO HAS NOT RECEIVED ANY REPORTS OF ADVERSE EVENTS RELATED TO RECALL OF SODIUM CHLORIDE INJECTION, USP, 0.9%.  Full Article

Fresenius Kabi Introduces Leukemia Drug Arsenic Trioxide Injection In 10 mg per 10 mL Vial
Friday, 26 Oct 2018 

Oct 26 (Reuters) - Fresenius Kabi::FRESENIUS KABI SAYS ANNOUNCES IMMEDIATE AVAILABILITY IN U.S. OF ARSENIC TRIOXIDE INJECTION IN A 10 MG PER 10 ML VIAL PRESENTATION.FRESENIUS KABI SAYS ARSENIC TRIOXIDE INJECTION IS FIRST-TO-MARKET GENERIC OF TRISENOX INDICATED FOR RELAPSED/REFRACTORY ACUTE PROMYELOCYTIC LEUKEMIA.  Full Article

Fresenius Says Simplist Palonosetron Hydrochloride Injection Available In The U.S
Monday, 22 Oct 2018 

Oct 22 (Reuters) - Fresenius SE & Co KGaA ::FRESENIUS KABI SAYS ANNOUNCED IMMEDIATE AVAILABILITY IN UNITED STATES OF SIMPLIST PALONOSETRON HYDROCHLORIDE INJECTION.  Full Article

Akorn Appeals Fresenius Kabi Ruling
Thursday, 18 Oct 2018 

Oct 18 (Reuters) - Akorn Inc ::AKORN APPEALS FRESENIUS KABI RULING.HAS ALSO FILED A MOTION SEEKING EXPEDITED PROCEEDINGS IN ITS APPEAL."DISAGREES WITH OPINION ISSUED OCTOBER 1 BY COURT OF CHANCERY".  Full Article

Fresenius drops possible sale of blood transfusion unit - spokesman

FRANKFURT, Sept 15 German health care group Fresenius has abandoned plans to sell its blood transfusion business, a spokesman said on Sunday, confirming a German media report.